Uncategorized
Real-world anti-VEGF injections produce slight decrease in IOP
BOSTON — A “significant but small decrease” in IOP was seen in patients receiving anti-VEGF injections, according to real-world analysis of IRIS Registry data presented in a poster here at the American Society of Retina Specialists meeting.However, while instances of clinically relevant IOP increase in these patients were “relatively rare,” repeated injections of Avastin (bevacizumab, Genentech) were seen to increase risk more than injections of Lucentis (ranibizumab, Genentech) or Eylea (aflibercept, Regeneron).